2024
Asthma control in the United States Relationships between short-acting β2-agonist and systemic corticosteroid use
Chupp G, Murphy K, Gandhi H, Gilbert I, Bleecker E. Asthma control in the United States Relationships between short-acting β2-agonist and systemic corticosteroid use. Annals Of Allergy Asthma & Immunology 2024, 133: 302-309. PMID: 38740134, DOI: 10.1016/j.anai.2024.05.003.Peer-Reviewed Original ResearchMild to moderate diseaseSystemic corticosteroidsMild-to-moderateSevere asthmaUncontrolled asthmaSystemic corticosteroid exposureSystemic corticosteroid useAsthma control assessmentCorticosteroid useExacerbation historyRetrospective analysisSABA useUS patientsPrescription fillsPatientsLongitudinal accessAsthma controlDisease severityAsthmaDiseaseExacerbationPearson correlation coefficientHigh symptom burdenPatient severitySymptom burden
2023
Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps
Chupp G, Alobid I, Lugogo N, Kariyawasam H, Bourdin A, Chaker A, Smith S, Sousa A, Mayer B, Chan R, Matucci A. Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps. The Journal Of Allergy And Clinical Immunology In Practice 2023, 11: 3504-3512.e2. PMID: 37586475, DOI: 10.1016/j.jaip.2023.08.015.Peer-Reviewed Original ResearchConceptsSevere chronic rhinosinusitisOral corticosteroid doseSystemic corticosteroidsNasal polypsChronic rhinosinusitisCorticosteroid doseSinus surgerySCS useTreatment responseLong-term adverse effectsPlacebo treatment responsePrior sinus surgeryPatient baseline characteristicsBlood eosinophil countsSystemic corticosteroid useMepolizumab efficacyCorticosteroid useWeek 52Baseline characteristicsEosinophil countClinical benefitCare treatmentMepolizumabRhinosinusitisPlacebo
2021
Mepolizumab Reduces Systemic Corticosteroid Use in Patients with Chronic Rhinosinusitis with Nasal Polyps
Chupp G, Alobid I, Lugogo N, Kariyawasam H, Bourdin A, Chaker A, Sousa A, Martin N, Yang S, Mayer B, Chan R, Matucci A. Mepolizumab Reduces Systemic Corticosteroid Use in Patients with Chronic Rhinosinusitis with Nasal Polyps. 2021, a1344-a1344. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1344.Peer-Reviewed Original Research
2020
Assessing Asthma Control in the United States by Examining the Relationships Between Short-Acting Beta 2 -Agonist and Systemic Corticosteroid Use
Bleecker E, Murphy K, Gandhi H, Gilbert I, Chupp G. Assessing Asthma Control in the United States by Examining the Relationships Between Short-Acting Beta 2 -Agonist and Systemic Corticosteroid Use. 2020, a1818-a1818. DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1818.Peer-Reviewed Original Research
2007
A Chitinase-like Protein in the Lung and Circulation of Patients with Severe Asthma
Chupp GL, Lee CG, Jarjour N, Shim YM, Holm CT, He S, Dziura JD, Reed J, Coyle AJ, Kiener P, Cullen M, Grandsaigne M, Dombret MC, Aubier M, Pretolani M, Elias JA. A Chitinase-like Protein in the Lung and Circulation of Patients with Severe Asthma. New England Journal Of Medicine 2007, 357: 2016-2027. PMID: 18003958, DOI: 10.1056/nejmoa073600.Peer-Reviewed Original ResearchConceptsSerum YKL-40 levelsYKL-40 levelsSeverity of asthmaYKL-40Chitinase-like proteinsParis cohortOral corticosteroid useCohort of patientsRescue inhaler useSubgroup of patientsCirculation of patientsCorticosteroid useSevere asthmaAirway remodelingClinical characteristicsExpiratory volumeAcidic mammalian chitinasePatient populationHigh serumAsthmaImmunohistochemical analysisPatientsAnimal modelsLocus of expressionMorphometric quantitation